

KIDMAN RESOURCES LTD (KDR)

Newsflow ahead: met work and maiden resource

Kidman has announced that metallurgy results for its Mt Holland lithium deposit are due imminently. We assume the results will be good; however, we are interested given the deposit appears to contain both spodumene and petalite. We don't expect the petalite will present any difficulties, but it will be good to see that the metallurgy confirms this assumption.

Subsequently, we expect the Company to release a maiden resource. We expect the resource to be large and at good grade. We see potential for a very large deposit (80-110Mt at good grades of 1.3-1.6% Li₂O) with possibility that the project becomes larger, particularly now that it appears to extend to the north.

Poseiden processing agreement

KDR has acquired an option (expires August 2017) to use and operate the Lake Johnston plant (owned by POS.asx) for 3+2 years. Upon exercise, KDR would be required to pay quarterly instalments of A\$1.5m (total of \$6m pa or a processing fee equivalent to \$10 per dry tonne, whichever is higher). The plant is ~100km by road from the Mt Holland deposit. Separately, POS says that if the nickel market improves, its strategy is to initially restart Silver Swan as a priority, while Maggie Hays and Emily Ann (at Lake Johnston) will take ~18 months of mine development, which POS could start ahead of the expiry of the lease to KDR. We assume KDR will have make good provisions for the mill to return it to a nickel processing plant. We also assume that the capex required for KDR to convert the plant into a spodumene plant will be more than \$8m (GMM/GXY budgeted ~\$15m to restart Mt Cattlin and subsequently have had to spend more).

Although it is a nice option to have, we believe the real value of Mt Holland is building a standalone operation which is designed for the orebody (ie product specification and a very long mine life). Entering production quickly is nice to happen, but, as PLS recently has shown, there appears to be potential for a DSO market in the next few years. We believe pursuing DSO product sales would be lower risk than re-commissioning an old plant (and then coincidently building and commissioning a new plant). Consequently, our speculative valuation assumes a standalone operation, which remains our base case.

Marindi (MZN) action...we assume no impact

KDR has said that "it does not have, nor has it ever had, a binding agreement with Marindi to sell the lithium rights at Mt Holland, and will continue to work with its legal counsel on this matter". The Company also states "that prior to the last few days, Marindi had not previously alleged any agreement, and in light of developments since April 2016, the Company views Marindi's actions as being opportunistic." We assume Marindi's actions will have no material effect on our KDR valuation, and hopefully can be resolved before January.

Retain Speculative Buy

Our preliminary and highly speculative unfunded pre-tax valuation is \$1bn, of which only \$60m is for the gold assets. Our valuation is based on a 2Mtpa operation, but it is possible that the operation could justify a larger mill, if the resource justifies it, and the Company is able to secure offtake.

| | 16 Nov 2016 |
|-------------------------|-------------|
| Share Price | \$0.460 |
| Prelim. Valuation | \$1.28 |
| Price Target (12 month) | \$1.07 |

Brief Business Description:

Excellent, but early stage, spodumene project in WA plus a good advanced gold exploration portfolio, also

Hartleys Brief Investment Conclusion

Appears to have a large undeveloped and good grade spodumene project. Under valued if the project can be developed

Chairman & MD

Peter Lester (Chairman)

Martin Donohue (MD)

Major Shareholders Capri 10.3%

Acorn 5.9%

Company Address


Level 4, 12-20 Flinders Lane Melbourne VIC 3000

Issued Capital 315.9m 365.8m Market Cap A\$145.3m - fully diluted A\$168.3m Cash (30 Sep 16a) A\$17.3m Debt (30 Sep 16a) A\$6.0m A\$134.0m EV/Resource Spod.

EV/Reserve Spod.

| Prelim. (A\$m) | F119e |
|----------------|-------|
| Prod (spod Mt) | nm |
| Op Cash Flw | nm |
| Norm NPAT | loss |
| CF/Share (cps) | nm |
| EPS (cps) | nm |
| P/E | nm |

| | Mt | grade | Moz | |
|-------------------------------|------|-------|-----|--|
| Resources (Li ₂ O) | none | | | |
| Reserve (Li ₂ O) | none | | | |
| | Mt | grade | Moz | |
| Resources (Au) | 20.0 | 1.8 | 1.2 | |
| Reserve (Au) | none | | | |



Trent Barnett

Head of Research

E: trent_barnett@hartleys.com.au Hartleys has assisted in the completion of capital raisings in the past 12 months for Kidman Resources Limited (Kidman), for which it has earned fees, Hartleys has provided corporate advice within the past 12 months, and continues to provide corporate advice to Kidman for which it has earned and continues to earn fees. Hartleys has a beneficial interest in 4 million unlisted options in Kidman. See back page for details.

SUMMARY MODEL

| Key Market Information | | | | | Directors | | | | Company De |
|---|----------|--|--|--|--|--|--------------------------------------|--|--|
| Share Price | | | | \$0.460 | | | | | |
| Market Capitalisation | | | | \$145.3m | Peter Lester (0 | | | | Level 4, 12-20 Flinders La |
| Market Capitalisation - full dil. | | | | \$168.3m | Martin Donohu | | | | Melbourne VIC : |
| Net Cash (Debt) | | | | \$11.3m | Brad Evans (n | on-exec) | | | ph: +61 3 9671 : |
| Listed Investments (est) | | | | \$0.0m | | | | | |
| ssued Capital | | | | 315.90m | | | | | |
| Options | | | | 49.9m | | | | | www.kidmanresources.com |
| ssued Capital (fully diluted all of | options) | | | 365.8m | | | | | |
| V - incl. listed invest | | | | \$134.0m | Top Sharehol | lders | | m shs | % |
| V - full diluted, option cash | | | | \$149.9m | Capri | | | 32.5 | 10.3% |
| rice Target | | | | \$1.07 | Acom | | | 18.5 | 5.9% |
| rojects | Interest | Location | C | ommodity | | | | | |
| t Holland - lithium | 100% | WA | | Li | Investment S | ummary | | | |
| It Holland - Gold | 100% | WA | | Au | | | | | |
| | | | | | | | | | |
| t Holland - Gold | 20.0 | 1.8 | 1.2 | | Nov/Dec Q1 CY17 early CY17 CY17 late CY17 | JORC Resource - Lithium Scoping Study - Lithium DFS - Gold DFS - Lithium commissioning Mt Holland | gold? | | Mt Holland - Li Mt Holland - Li Mt Holland - Gold Mt Holland - Li |
| | | | | | 0)/40 | Control of the Contro | | | Mt Holland - Gold |
| | | | | | CY18 | first spodumene sales? | 6 () | Avv Da | Mt Holland - Li |
| | | | | | CY18 Unpaid Capita | | \$ (m) | Ave Pr | |
| SL. | | FY2017F | FY2018F | FY2019F | | | \$ (m) | Ave Pr | Mt Holland - Li |
| | | FY2017F na | FY2018F na | FY2019F na | Unpaid Capita | | \$ (m) 0.00 | Ave Pr | Mt Holland - Li |
| et Revenue | | | | | Unpaid Capital | al No (m) | | | Mt Holland - Li % Ord |
| et Revenue otal Costs | | na | na | na | Unpaid Capital Options 30-Jun-17 | al No (m) | 0.00 | nm | Mt Holland - Li % Ord 0.0% |
| et Revenue otal Costs BITDA | | na na | na na | na na | Options 30-Jun-17 30-Jun-18 | No (m) 0 0 | 0.00 | nm nm | Mt Holland - Li % Ord 0.0% 0.0% |
| et Revenue otal Costs BITDA eprec/Amort | | na na na | na na na | na na na | Options 30-Jun-17 30-Jun-18 30-Jun-19 | 0 0 47 | 0.00 0.00 7.12 | nm nm 0.150 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% |
| et Revenue otal Costs BITDA eprec/Amort BIT | | na na na na | na na na na | na na na na | Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 | 0 0 47 0 | 0.00 0.00 7.12 0.00 | nm nm 0.150 nm | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% |
| et Revenue otal Costs BITDA eprec/Amort BIT et Interest | | na na na na na | na na na na na | na na na na na | Unpaid Capit Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 | 0 0 47 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% |
| et Revenue otal Costs BITDA eprec/Amort BIT et Interest re-Tax Profit | | na na na na na | na na na na na | na na na na na | Unpaid Capit Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| et Revenue otal Costs BITDA eprec/Amort BIT et Interest re-Tax Profit ax Expense | | na na na na na na | na na na na na na | na na na na na na | Unpaid Capit Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| et Revenue otal Costs BITDA eprec/Amort BIT et Interest re-Tax Profit ax Expense PAT | | na na na na na na na | na na na na na na na | na na na na na na na | Unpaid Capital Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 Total | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| et Revenue otal Costs BITDA epprec/Amort BIT et Interest re-Tax Profit ax Expense PAT onormal Items | | na | na na na na na na na | na na na na na na na | Unpaid Capital Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 Total | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| et Revenue otal Costs BITDA epprec/Amort BIT et Interest re-Tax Profit ax Expense PAT onormal Items | | na | na na na na na na na na | na na na na na na na na | Unpaid Capital Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 Total | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| &L et Revenue otal Costs BITDA epprec/Amort BIT let Interest re-Tax Profit ax Expense PAT bnormal Items eported Profit | | na | na na na na na na na na | na na na na na na na na | Unpaid Capital Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 Total | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |
| et Revenue otal Costs BITDA epprec/Amort BIT et Interest re-Tax Profit ax Expense PAT bnormal Items eported Profit | | na | na na na na na na na na | na na na na na na na na | Unpaid Capital Options 30-Jun-17 30-Jun-18 30-Jun-19 30-Jun-20 30-Jun-21 30-Jun-22 Total | 0 0 47 0 0 | 0.00 0.00 7.12 0.00 0.00 | nm nm 0.150 nm nm 0.000 | Mt Holland - Li % Ord 0.0% 0.0% 13.1% 0.0% 0.0% 0.8% |

| Fig. 1: Key Assump | tions and Risks for | valuation | |
|---|-------------------------------------|--|---|
| Assumption | Risk of not realising assumption | Downside risk to valuation if assumption is incorrect | Comment |
| An economic hardrock lithium deposit can be defined. | Moderate | Extreme | This appears reasonable based on drilling to date, but still speculative |
| Selling prices remain strong enough for spodumene mines to be viable | High | Extreme | We assume selling prices and demand remain strong enough for new spodumene mines to be developed |
| The Poseidon agreement is not used and the Company builds a new greenfields operation | Moderate | Upside | We assume KDR will develop Mt Holland as a standalone operation. If capex can be saved using neighbouring infrastructure this could improve economics |
| Company can obtain capital | High | Extreme | We assume KDR can continue to raise capital for development and exploration |
| Meaningful value for the gold assets | Moderate | High | We speculatively assign \$55m of value for the gold assets |
| Exploration value | Moderate | Meaningful | We assume speculative mining inventory assumptions and additionally some extra some exploration value. |
| Conclusion | We have used specula | tive assumptions to deri | ve a valuation. Hence, we view KDR as high risk. |

Source: Hartleys

PRICE TARGET

We have a price target of \$1.07 (from \$1.31).

| Price Target Methodology | Weighting | Spot | 12 mth out |
|---|-----------|---------|------------|
| Speculative NPV base case, assuming significant equity dilution | 45% | \$1.28 | \$1.49 |
| Speculative NPV at spot commodity and fx prices | 20% | \$1.64 | \$1.91 |
| Net cash | 35% | \$0.05 | \$0.05 |
| | | | |
| Risk weighted composite | | \$0.92 | |
| 12 Months Price Target | | \$1.07 | |
| Shareprice - Last | | \$0.460 | |
| 12 mth total return (% to 12mth target + dividend) | | 133% | |

Source: Hartleys Estimate

RISKS

Exploration success in defining an economic deposit is still the largest risk for KDR.

Adjacent to this risk, is the ability for the Company to sign offtakes for the product to provide certainty for financers. Additionally, the prices for spodumene are a risk. Eventually, other risks are similar to most developers: the outcomes of more detailed studies, metallurgy, management key-man risk, obtaining finance, relevant government approvals, political risk, commodity prices, commissioning success and the asset performance versus nameplate design.

Our valuation is very speculative given it is pre-resource and pre any studies.

HARTLEYS CORPORATE DIRECTORY

Research

| Trent Barnett | Head of Research | +61 8 9268 3052 |
|---------------------|--------------------|-----------------|
| Mike Millikan | Resources Analyst | +61 8 9268 2805 |
| John Macdonald | Resources Analyst | +61 8 9268 3020 |
| Michael Scantlebury | Junior Analyst | +61 8 9268 3045 |
| Janine Bell | Research Assistant | +61 8 9268 2831 |
| | | |

Corporate Finance

| Dale Bryan | Director & Head of | +61 8 9268 2829 |
|------------|--------------------|-----------------|
| | | |

Corp Fin.

Director +61 8 9268 2824 Richard Simpson Director +61 8 9268 2819 Paul Fryer Associate Director Ben Wale +61 8 9268 3055 Associate Director Ben Crossing +61 8 9268 3047 Stephen Kite Associate Director +61 8 9268 3050 Scott Weir Associate Director +61 8 9268 2821 Rhys Simpson Manager +61 8 9268 2851

Registered Office

Level 6, 141 St Georges TcePostal Address:

PerthWA 6000 GPO Box 2777

Australia Perth WA 6001

PH:+61 8 9268 2888 FX: +61 8 9268 2800

www.hartleys.com.au info@hartleys.com.au

Note: personal email addresses of company employees are

structured in the following

manner:firstname_lastname@hartleys.com.au

Hartleys Recommendation Categories

Buy Share price appreciation anticipated.

Accumulate Share price appreciation anticipated but the risk/reward is

not as attractive as a "Buy". Alternatively, for the share price to rise it may be contingent on the outcome of an uncertain or distant event. Analyst will often indicate a

price level at which it may become a "Buy".

Neutral Take no action. Upside & downside risk/reward is evenly

balanced.

Reduce / It is anticipated to be unlikely that there will be gains over Take profits the investment time horizon but there is a possibility of

some price weakness over that period.

Sell Significant price depreciation anticipated.

No Rating No recommendation.

Speculative Share price could be volatile. While it is anticipated that, Buy on a risk/reward basis, an investment is attractive, there

on a risk/reward basis, an investment is attractive, there is at least one identifiable risk that has a meaningful possibility of occurring, which, if it did occur, could lead to significant share price reduction. Consequently, the

investment is considered high risk.

Institutional Sales

| Carrick Ryan | +61 8 9268 2864 |
|--------------------|-----------------|
| Justin Stewart | +61 8 9268 3062 |
| Simon van den Berg | +61 8 9268 2867 |
| Chris Chong | +61 8 9268 2817 |
| Digby Gilmour | +61 8 9268 2814 |
| Cooper Rogers | ±61 8 9268 3053 |

Cooper Rogers +61 8 9268 3053 Wealth Management Nicola Bond +61 8 9268 2840 **Bradley Booth** +61 8 9268 2873 Adrian Brant +61 8 9268 3065 Nathan Bray +61 8 9268 2874 Sven Burrell +61 8 9268 2847 Simon Casey +61 8 9268 2875 Tony Chien +61 8 9268 2850 Tim Cottee +61 8 9268 3064 +61 8 9268 2860 David Cross Nicholas Draper +61 8 9268 2883 John Featherby +61 8 9268 2811 Ben Fleav +61 8 9268 2844 James Gatti +61 8 9268 3025 +61 8 9268 2890 John Goodlad Andrew Gribble +61 8 9268 2842 David Hainsworth +61 8 9268 3040 **Neil Inglis** +61 8 9268 2894 Murray Jacob +61 8 9268 2892 Gavin Lehmann +61 8 9268 2895 Shane Lehmann +61 8 9268 2897 Steven Loxley +61 8 9268 2857 Andrew Macnaughtan +61 8 9268 2898 Scott Metcalf +61 8 9268 2807 David Michael +61 8 9268 2835 Jamie Moullin +61 8 9268 2856 Chris Munro +61 8 9268 2858 Michael Munro +61 8 9268 2820 Ian Parker +61 8 9268 2810 Charlie Ransom +61 8 9268 2868 Mark Sandford +61 8 9268 3066 David Smyth +61 8 9268 2839 Greg Soudure +61 8 9268 2834 Sonya Soudure +61 8 9268 2865 Dirk Vanderstruyf +61 8 9268 2855

+61 8 9268 3041

+61 8 9268 2828

Samuel Williams

Jayme Walsh

Disclaimer/Disclosure

The author of this publication, Hartleys Limited ABN 33 104 195 057 ("Hartleys"), its Directors and their Associates from time to time may hold shares in the security/securities mentioned in this Research document and therefore may benefit from any increase in the price of those securities. Hartleys and its Advisers may earn brokerage, fees, commissions, other benefits or advantages as a result of a transaction arising from any advice mentioned in publications to clients.

Hartleys has assisted in the completion of capital raisings in the past 12 months for Kidman Resources Limited (Kidman), for which it has earned fees. Hartleys has provided corporate advice within the past 12 months, and continues to provide corporate advice to Kidman for which it has earned and continues to earn fees. Hartleys has a beneficial interest in 4 million unlisted options in Kidman.

Any financial product advice contained in this document is unsolicited general information only. Do not act on this advice without first consulting your investment adviser to determine whether the advice is appropriate for your investment objectives, financial situation and particular needs. Hartleys believes that any information or advice (including any financial product advice) contained in this document is accurate when issued. Hartleys however, does not warrant its accuracy or reliability. Hartleys, its officers, agents and employees exclude all liability whatsoever, in negligence or otherwise, for any loss or damage relating to this document to the full extent permitted by law.